Literature DB >> 7347565

Effects of ethambutol on phospholipid metabolism in Mycobacterium smegmatis.

J O Kilburn, K Takayama, E L Armstrong, J Greenberg.   

Abstract

Soon after Mycobacterium smegmatis was exposed to ethambutol, the synthesis of cardiolipin and phosphatidylinositol dimannoside declined. The synthesis of phosphatidylethanolamine continued, but the drug caused this phospholipid to leak out of the cells.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7347565      PMCID： PMC181426          DOI： 10.1128/AAC.19.2.346

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  4 in total

1.  A SIMPLE, SPECIFIC SPRAY FOR THE DETECTION OF PHOSPHOLIPIDS ON THIN-LAYER CHROMATOGRAMS.

Authors:  J C DITTMER; R L LESTER
Journal:  J Lipid Res       Date:  1964-01       Impact factor: 5.922

2.  Secretion of lipids induced by inhibition of peptidoglycan synthesis in streptococci.

Authors:  D Horne; R Hakenbeck; A Tomasz
Journal:  J Bacteriol       Date:  1977-11       Impact factor: 3.490

3.  Inhibition by ethambutol of mycolic acid transfer into the cell wall of Mycobacterium smegmatis.

Authors:  K Takayama; E L Armstrong; K A Kunugi; J O Kilburn
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

4.  Effect of ethambutol on the viable cell count in Mycobacterium smegmatis.

Authors:  J O Kilburn; J Greenberg
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191
  4 in total
  15 in total

1.  Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations.

Authors:  S Sreevatsan; K E Stockbauer; X Pan; B N Kreiswirth; S L Moghazeh; W R Jacobs; A Telenti; J M Musser
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 2.  Treatment of pulmonary disease caused by opportunist mycobacteria.

Authors:  J Banks
Journal:  Thorax       Date:  1989-06       Impact factor: 9.139

3.  Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis.

Authors:  S V Ramaswamy; A G Amin; S Göksel; C E Stager; S J Dou; H El Sahly; S L Moghazeh; B N Kreiswirth; J M Musser
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  Nucleotide polymorphism associated with ethambutol resistance in clinical isolates of Mycobacterium tuberculosis.

Authors:  S Srivastava; A Garg; A Ayyagari; K K Nyati; T N Dhole; S K Dwivedi
Journal:  Curr Microbiol       Date:  2006-09-12       Impact factor: 2.188

5.  Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis.

Authors:  K Takayama; J O Kilburn
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 6.  Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.

Authors:  Sumit Chakraborty; Kyu Y Rhee
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-15       Impact factor: 6.915

7.  Development and biological evaluation of a new nanotheranostic for tuberculosis.

Authors:  Edward Helal-Neto; Suyene Rocha Pinto; Filipe Leal Portilho; Marcellus Dias da Costa; Jonathas Xavier Pereira; Fiammetta Nigro; Eduardo Ricci-Junior; Andre Luis Peixoto Candéa; Maria das Graças Muller de Oliveira Henriques; Ralph Santos-Oliveira
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

8.  Mycobacterium tuberculosis embB codon 306 mutations confer moderately increased resistance to ethambutol in vitro and in vivo.

Authors:  Claudia Plinke; Kerstin Walter; Sahar Aly; Stefan Ehlers; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

9.  Cell wall and membrane changes associated with ethambutol resistance in Mycobacterium tuberculosis H37Ra.

Authors:  M Sareen; G K Khuller
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

10.  Ethambutol inhibition of glucose metabolism in mycobacteria: a possible target of the drug.

Authors:  G Silve; P Valero-Guillen; A Quemard; M A Dupont; M Daffe; G Laneelle
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.